

Sartorius AG

2023

Financial Statements

Contents

Financial Statements and Notes	3
Balance Sheet as of December 31, 2023	4
Statement of Profit and Loss for the Period of January 1 to December 31, 2023	6
Notes to the Financial Statements for Fiscal 2023	7
Notes to the Individual Balance Sheet Items	10
Notes to the Statement of Profit and Loss	15
Other Disclosures	19
Declaration of the Executive Board	23
Independent Auditor's Report	24
Supplementary Information	31
Development of Fixed Assets	32
Share Ownership	34
Executive Board and Supervisory Board	38
About This Publication	48

Forward-looking Statements Contain Risks

This annual report contains statements concerning the future performance of Sartorius AG. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually apply. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements. This is a translation of the original German-language financial statements. Sartorius shall not assume any liability for the correctness of this translation. The original German financial statements are the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Throughout these financial statements, differences may be apparent as a result of rounding during addition.

Balance Sheet as of December 31, 2023

Assets (in millions of €)	Notes	Dec. 31, 2023		Dec. 31, 2022	
A. Assets					
I. Intangible assets	[1]				
Purchased concessions, industrial property rights and similar rights as well as licenses for such rights and assets			7.4		12.9
II. Property, plant and equipment	[2]				
1. Land and leasehold rights and improvements, including buildings on third-party land		125.6		130.1	
2. Factory and office equipment and other equipment		2.5		2.7	
3. Payments on account and construction in progress		0.9	129.0	0.2	133.0
III. Financial assets	[3]				
1. Shares in affiliated companies		439.2		439.2	
2. Loans to affiliated companies		1,653.5		2,158.9	
3. Investments (participating interest)		0.0		0.0	
4. Other loans		5.1	2,097.8	4.4	2,602.5
			2,234.2		2,748.4
B. Current assets					
I. Trade and other receivables	[4]				
1. Receivables from affiliated companies		178.8		115.9	
2. Other assets		0.6	179.4	1.9	117.8
II. Cash on hand, deposits in banks			222.5		4.4
			401.9		122.2
C. Prepaid expenses	[5]		2.8		3.5
			2,638.9		2,874.1

Equity and Liabilities (in millions of €)	Notes	Dec. 31, 2023	Dec. 31, 2022
A. Equity			
I. Subscribed capital	[6]	74.9	74.9
Nominal value of treasury shares		-6.5	-6.5
Issued capital		68.4	68.4
II. Capital reserves	[7]	59.6	59.0
III. Earnings reserves	[8]	10.9	10.9
IV. Retained profit incl. net profit	[8]	283.0	267.1
		421.9	405.4
B. Provisions	[9]		
1. Provisions for retirement benefits and similar obligations		22.5	22.2
2. Tax provisions		4.1	5.2
3. Other provisions		7.6	9.6
		34.2	37.0
C. Liabilities	[10]		
1. Liabilities to banks		2,144.2	2,394.0
2. Trade payables		0.6	1.5
3. Payables to affiliated companies		34.0	27.1
4. Other liabilities			
- Of which tax liabilities of 2.7 (2022: 0.1) -		4.0	9.1
		2,182.8	2,431.7
		2,638.9	2,874.1

Statement of Profit and Loss for the Period of January 1 to December 31, 2023

in millions of €	Notes	2023	2022
1. Sales revenue	[13]	17.5	20.0
2. Other operating income	[14] [24]	7.3	67.7
3. Employee benefits expense	[15]		
a) Salaries		-5.6	-5.8
b) Social security and retirement benefits expense and support - Of which for the General Pension Plan -1.1 (2022: -1.4) -		-1.1	-1.4
		-6.7	-7.2
4. Depreciation of property, plant and equipment and amortization of intangible assets	[16]	-10.4	-9.9
5. Other operating expenses	[17] [24]	-27.8	-18.9
6. Income from investments - Of which from affiliated companies 97.7 (2022: 85.5) -	[18]	97.7	85.5
7. Income from long-term loans - Of which from affiliated companies 47.1 (2022: 21.7) -	[19]	47.1	21.7
8. Profit received under a profit and loss transfer agreement	[20]	60.8	19.5
9. Interest and similar income - Of which from affiliated companies 20.2 (2022: 1.4) -	[21]	31.8	2.7
10. Write downs on financial assets and short-term investments	[22]	-20.0	0.0
11. Interest and similar expenses - Of which paid or reimbursed to affiliated companies -5.3 (2022: 0.0) -	[21]	-80.3	-26.4
12. Income tax expense	[23] [24]	-2.0	-0.1
13. Profit after tax		115.0	154.6
14. Other taxes		-0.9	-0.1
15. Net profit for the period		114.1	154.5
16. Profit brought forward		168.9	112.6
17. Retained profit incl. net profit for the period		283.0	267.1

Notes to the Financial Statements for Fiscal 2023

Accounting and Valuation Methods

Sartorius AG is a listed joint stock corporation within the meaning of Section 264 d of the German Commercial Code (HGB). Sartorius AG is headquartered in Göttingen, Germany, and is recorded in the German Commercial Register B of the District Court of Göttingen ("Amtsgericht Göttingen") under the number of HRB 1970.

The financial statements for Sartorius AG were prepared according to the accounting rules of the German Commercial Code (HGB) and the provisions of the German Stock Corporation Law (AktG), and the figures are reported in millions of euros. The statement of profit and loss was prepared according to the total cost method.

The accounting and valuation methods of the previous reporting year were retained.

Intangible Assets

Intangible assets purchased are measured at cost. They are amortized over their useful lives as scheduled using the straight-line method. Internally generated intangible assets are not capitalized.

Property, Plant and Equipment

Property, plant and equipment are reported at acquisition cost or production cost and, if subject to depreciation, are depreciated as scheduled. Where diminution in value is anticipated over the long term, unscheduled impairment losses are recorded. Write-downs are reversed up to the amount of the recoverable acquisition cost if the reasons for permanent impairment no longer exist. Property, plant and equipment are depreciated according to the straight-line method. Additions to such tangible assets are depreciated on a pro-rated basis as of the year they are acquired. Depreciable fixed assets are recognized at cost (acquisition or production cost) up to €250 directly in expenses in the year they are purchased by applying the tax rule for low-value assets. This accounting rule is applied with a depreciation period of one year (100% write-off in the year acquired) to assets whose acquisition or production cost is between €250 and €800.

Financial Assets

Financial assets are measured at cost or at their lower fair value. Where diminution in value is anticipated over the long term, unscheduled impairment losses are recorded. Write-downs are reversed up to the amount of the recoverable acquisition cost if the reasons for permanent impairment no longer exist.

Current Assets

Trade and other receivables are measured at their nominal value or at their lower daily value.

Provisions

Retirement and pension obligations are measured according to the projected unit credit method. The calculation of such liabilities is based on actuarial expert opinions that take recognized biometric assumptions into account.

Tax provisions and other provisions are measured so that they cover all discernible risks. Provisions are recognized at the settlement amounts required; non-current provisions are discounted over their remaining term at the average market interest rate that has been determined and announced by the Deutsche Bundesbank.

Liabilities

Liabilities are recognized at their settlement amounts as of the reporting date.

Currency Translation

Foreign currency assets and liabilities are recognized at the average spot rate valid at the time of the particular transaction.

Assets in foreign currencies whose remaining term does not exceed one year are measured at the average spot rate valid on the reporting date. All other receivables in foreign currencies are assessed at their conversion rate upon the invoice date or the lower average spot rate on the reporting date.

Liabilities in foreign currencies whose remaining term does not exceed one year are measured at the average spot rate valid on the reporting date. All other liabilities in foreign currencies are measured at their conversion rate upon the invoice date or the higher average spot rate on the reporting date.

Taxes

Deferred Taxes

The temporary concept is used to calculate deferred taxes. These deferred taxes are assessed for temporary differences between commercial accounting and tax accounting of assets, liabilities and prepaid expenses in Germany. This valuation not only includes the differences arising from Sartorius AG's own balance sheet items, but also those that exist for subsidiaries ("receiving entities") or business partnerships or other non-corporate entities in which Sartorius AG holds an investment. Deferred taxes are assessed on the basis of the combined income tax rate for Sartorius AG, which is currently 30.0%. The combined income tax rate covers corporate income tax, industrial and commercial profits tax and the solidarity surcharge on income tax for reconstruction of eastern Germany. However, unlike in the former case, deferred taxes from temporary accounting differences for investments that have the legal form of a business partnership or a non-corporate entity are measured on the basis of a combined income tax rate, which covers only corporate income tax and the solidarity surcharge on income tax; this particular income tax rate is currently 15.83%. Deferred taxes are reported as amounts netted out. If an overall tax burden were to be yielded by these calculations, this would be disclosed as deferred tax liabilities.

Sartorius AG has tax loss carry-forwards for corporate and commercial income tax.

Deferred tax assets on these loss carry-forwards were considered in the amounts in which they are likely to be recoverable in the future from today's viewpoint.

The deferred taxes reported essentially result from valuation differences in the intangible assets and provisions as well as from the future use of tax loss carry-forwards. The option provided by Section 274 (1) sentence 2, of the German Commercial Code (HGB) was exercised so that deferred tax assets resulting on the whole were not recognized.

International Tax Reform – Pillar 2 – Global Minimum Tax

The objective of a global minimum tax (Pillar 2) for large corporations is that the relevant companies pay an effective income tax of at least 15%. Because the regulations were not yet in effect in the reporting period, there are no tax-related impacts in the year 2023. In December 2023, Germany passed a law on the implementation of the minimum tax. Sartorius AG is thus subject to the minimum tax beginning in 2024 as the parent company of the group. Based on the current status of the analysis, in consideration of the safe harbor rules that apply for at least 2024 and the two following years, Sartorius AG does not expect any material impact from the new regulation in the foreseeable future. There could potentially be a minimal impact on the activities of the subsidiaries in Ireland (nominal tax rate: 12.5%).

Notes to the Individual Balance Sheet Items

1. Intangible Assets

Intangible assets are amortized over a period of use of 5 years.

Please refer to the table "Development of Fixed Assets."

2. Property, Plant and Equipment

Factory and office buildings as well as distribution facilities are essentially depreciated over 33 years; factory and office equipment and other equipment are predominantly written off in 1 to 13 years.

Please refer to the table "Development of Fixed Assets."

3. Financial Assets

Please refer to the table "Development of Fixed Assets."

4. Trade and Other Receivables

in millions of €	Dec. 31, 2023	Dec. 31, 2022
Receivables from affiliated companies	178.8	115.9
Other assets	0.6	1.9
	179.4	117.8

The receivables from affiliated companies essentially include short-term financial receivables.

As in the previous year, trade and other receivables have a remaining term of up to one year.

5. Prepaid Expenses

The prepaid expenses essentially include loan discounts that are released over the term of the respective finance loans.

6. Issued Capital

Sartorius AG's capital stock is divided into 37,440,000 bearer-type ordinary shares and 37,440,000 non-voting preference shares, each having a calculated par value of €1.00.

As of the reporting date, the company holds 3,213,991 ordinary shares and 3,250,147 preference shares that were purchased in the years of 2000 to 2001 based on the authorization granted at the Annual General Meeting on June 21, 2000. This equals a shareholding of €6.5 million (8.7%) of the share capital issued. These shares are held in particular as currency for future acquisitions of companies. In fiscal 2023, no treasury shares were purchased.

The calculated par value of the treasury shares of €6.5 million was deducted from the capital stock according to Section 272 (1a), of the German Commercial Code (HGB).

Subject to approval by the Supervisory Board, the Executive Board is authorized to sell treasury shares held by the corporation, including sales through channels other than the stock exchange or by tendering an offer to all shareholders in proportion to their participation in the company, provided that these shares are offered within the scope of acquiring companies or shareholdings in companies in return. Under these circumstances, the pre-emptive rights of the shareholders are excluded.

The Supervisory Board is authorized to use treasury shares of the company to transfer these to members of the company's Executive Board as part of their remuneration.

7. Capital Reserves

in millions of €	
As of Jan. 1, 2023	59.0
+ Granting of share-based payments to members of the Executive Board	0.6
As of Dec. 31, 2023	59.6

As a result of the granting of share-based remuneration to the members of the Executive Board in the fiscal year, the capital reserves increased by €0.6 million compared with the previous year.

8. Earnings Reserves and Retained Profit

The earnings reserves according to Section 266 (3) III, No. 4, of the German Commercial Code (HGB) remained unchanged at €10.9 million.

In fiscal 2023, the earnings reserves developed as follows:

in millions of €	
As of Jan. 1, 2023	267.1
Dividends paid in 2023	-98.2
Profit carried forward	168.9
Net profit for 2023	114.1
As of Dec. 31, 2023	283.0

9. Provisions

in millions of €	Dec. 31, 2023	Dec. 31, 2022
Provisions for employee retirement benefits and similar obligations	22.5	22.2
Tax provisions	4.1	5.2
Other provisions	7.6	9.6
	34.2	37.0

Provisions for retirement benefits are set up according to actuarial principles in line with the valuation assumptions and methods pursuant to Section 249 (1), of the German Commercial Code (HGB) in conjunction with Section 253 of HGB.

	End of the reporting year	Beginning of the reporting year
Accounting standards applied		HGB
Assessment standards applied	Projected Unit Credit Method (PUCM)	
Biometric assumptions:		
- Assumptions on mortality and invalidity	Ref. interest rate table "Richttafel 2018 G" from Klaus Heubeck	
- Fluctuation		None
- Calculated retirement age		Early retirement age limits
Business assumptions:		
- Annual discount rates acc. to RückAbzinsV (simplification rule: interest rate for remaining period of 15 years)		
Average of the last 10 years	1.83%	1.78%
Average of the last 7 years	1.76%	1.44%
- Expected annual increase in old-age pensions	2.10%	2.10%
- Expected annual increase in income		
Individually agreed pension plans	3.00%	3.00%
General in-house retirement plan	-	-

Insolvency-protected investments in reinsurance policies to hedge obligations for early retirement benefits that were reported at a present value of €0.2 million (2022: €0.2 million) and correspond to the acquisition costs were offset against the present value of the respective retirement benefits of €1.3 million (2022: 1.2 million).

Provisions for employee retirement benefits and similar obligations developed as following during fiscal 2023:

in millions of €	
Gross provisions as of Jan. 1, 2023	22.4
Interest expense	0.4
Effect of the change in the actuarial interest rate	-0.1
Pension payments	-1.1
Other changes	1.1
Gross provisions as of Dec. 31, 2023	22.7
Reinsurance reserves for hedging obligations acc. to Sec. 246, Subsec. 2, of HGB, as of Dec. 31, 2023 (present value of pledged reinsurance policies)	0.2
Net provisions as of Dec. 31, 2023	22.5

Besides allowing for Sartorius AG's general in-house retirement plan, these provisions are set aside to meet individually agreed pension plans for active and former Executive Board members and senior corporate officers. Since the termination of the General Pension Plan "Versorgungswerk" in 1983, the portion of the general provisions is only for employees who began their employment with the company before January 1, 1983. A total of €6.6 million of the reserves set up as of December 31, 2023, is allocated to Sartorius AG's general in-house retirement plan, and €16.1 million to cover individually agreed pension plans. The present values of the obligations for active Executive Board members are €5.2 million to cover pension commitments for Dr. Joachim Kreuzburg (2022: €4.7 million), €0.4 million to cover those for René Fáber (2022: €0.2 million). Effects from the change in accounting interest are recognized in the financial result.

If the 7-year annual interest rate were to be used, provisions for retirement benefits and similar obligations would amount to €22.9 million (2022: €23.1 million); the difference would accordingly total €0.2 million (2022: €0.8 million) and would be barred from profit distribution under Section 253 (6), of HGB, taking into account deferred tax liabilities.

The other provisions include the following amounts:

in millions of €	Dec. 31, 2023	Dec. 31, 2022
Employee benefits expense	6.0	6.9
Invoices outstanding	1.7	2.7
Other	0.0	0.0
	7.7	9.6

10. Liabilities

This item consists of the following:

in millions of €	Disclosed on balance sheet	Remaining term of		
	Dec. 31, 2023	up to one year	one to five years	more than five years
Liabilities to banks	2,144.2	213.4	1,413.7	517.1
Trade payables	0.6	0.6	0.0	0.0
Payables to affiliated companies	34.0	34.0	0.0	0.0
Other liabilities	4.0	4.0	0.0	0.0
	2,182.8	252.0	1,413.7	517.1

in millions of €	Disclosed on balance sheet	Remaining term of		
	Dec. 31, 2022	up to one year	one to five years	more than five years
Liabilities to banks	2,394.0	522.0	1,389.9	482.1
Trade payables	1.5	1.5	0.0	0.0
Payables to affiliated companies	27.1	27.1	0.0	0.0
Other liabilities	9.1	9.1	0.0	0.0
	2,431.7	559.7	1,389.9	482.1

The payables to affiliated companies essentially include short-term financial receivables.

Liabilities to banks include interest liabilities in the amount of €9.7 million. In the previous year, this figure was €8.1 million and was reported under other liabilities.

No collateral has been provided for the company's own liabilities.

11. Contingent Liabilities

Guarantee and suretyship contracts for the amount of €152.4 million (2022: €101.8 million) were concluded to cover the contingent liabilities arising from local credit lines granted by banks to various affiliates of Sartorius AG. These are not to be recognized because there are no signs that the local subsidiaries will fail to meet their financial obligations to banks on time.

In addition, Sartorius AG issued a guarantee on behalf of Sartorius Finance B.V. as part of the bond issue of a nominal amount of €3,000 million. This guarantees the proper and timely payment of capital and interest on the debenture bond as well as any other amounts payable in conjunction with the debenture bond.

Sartorius AG has issued a comfort letter on behalf of Sartorius Lab Instruments GmbH & Co. KG with an initial validity through December 31, 2023.

In addition, Sartorius AG has issued comfort letters on behalf of Sartorius Stedim BioOutsource Ltd., Sartorius Stedim Chromatography Systems Ltd., Sartorius Stedim Lab Ltd., Sartorius Stedim UK Ltd., Sartorius UK Ltd., and The Automation Partnership (Cambridge) Ltd., with initial validity through December 15, 2024.

12. Other Financial Liabilities

In addition to provisions, liabilities and contingent liabilities, other financial obligations essentially consist of rental and lease contracts.

in millions of €	Dec. 31, 2023	Dec. 31, 2022
Due within one year	0.1	0.1
Due in one to five years	0.0	0.0
	0.1	0.1

Notes to the Statement of Profit and Loss

13. Sales Revenue

Sales revenue, which is broken down by geographical market and main area of activity, was as follows:

in millions of €	2023	2022
Sales revenue for Germany		
Sales revenue from rentals	12.0	12.0
Sales revenue from services provided	4.7	6.5
	16.7	18.5
Sales revenue for all other countries		
Sales revenue from services provided	0.8	1.5
	0.8	1.5
	17.5	20.0

14. Other Operating Income

in millions of €	2023	2022
Income from affiliated companies	7.0	0.1
Income from currency translation	0.1	0.1
Book profits from asset sales	0.0	67.3
Income from the release of provisions	0.0	0.1
Other income	0.2	0.1
	7.3	67.7

Income from affiliated companies results from the intra-group transfer of financing expenses as part of an acquisition.

15. Employee Benefits Expense

in millions of €	2023	2022
Salaries	-5.6	-5.8
Social security	0.0	0.0
Retirement benefits expense and support	-1.1	-1.4
	-6.7	-7.2

The employee benefits expense disclosed refers to benefits for the Executive Board of Sartorius AG.

16. Depreciation Expenses

Depreciation of property, plant and equipment and amortization of intangible assets:

in millions of €	2023	2022
Scheduled	-10.4	-9.9

17. Other Operating Expenses

in millions of €	2023	2022
Other financing expenses	-8.1	-0.4
Expenses with affiliated companies	-6.6	-6.1
Costs for outside services	-4.0	-6.3
Legal and consulting expenses	-3.3	-1.5
Maintenance costs	-1.6	-1.5
Remuneration for the Supervisory Board	-1.5	-0.9
Fees and contributions	-0.9	-0.6
Travel, entertainment and representation costs	-0.4	-0.5
Rent, car and leasing expenses	-0.2	-0.2
Ancillary staff costs	-0.1	-0.2
Expenses from currency translation	-0.1	-0.2
Losses from asset disposals	-0.1	0.0
Other operation expenses	-0.9	-0.5
	-27.8	-18.9

The other financing expenses essentially result from bridge financing as part of an acquisition.

18. Income from Investments

in millions of €	2023	2022
Income from investments	97.7	85.5

As in the previous year, the entire amount of Sartorius AG's income from investments consists of dividend payments from subsidiaries.

19. Income from Long-term Loans

The entire amount of income from long-term loans was related to income from affiliated companies.

20. Profit Received / Loss Accepted under a Profit and Loss Transfer Agreement

in millions of €	2023	2022
Sartorius Lab Holding GmbH	45.0	7.6
Sartorius Corporate Administration GmbH	15.8	11.9
	60.8	19.5

21. Interest

in millions of €	2023	2022
Interest and similar income	31.8	2.7
- Of which from affiliated companies -	(20.2)	(1.4)
Interest and similar expenses	-80.3	-26.4
- Of which paid or reimbursed to affiliated companies -	(-5.3)	(0.0)
	-48.5	-23.7

The increase in interest expenses for Sartorius AG compared with the previous year is due, on the one hand, to the taking out of a note loan ("Schuldscheindarlehen") in the amount of €650 million in November 2022, parts of which were not paid out until 2023 and thus were not fully recognized in interest expenses until 2023. On the other hand, interest expenses stem from the bridge financing taken out during the year under review in the amount of €2.45 billion to finance the Polyplus acquisition, which was replaced by the bonds issued by Sartorius Finance B.V.

Additionally, in light of the proportion of variable-interest loans, an increase in interest rates compared with the previous year led to an increase in interest expenses for Sartorius AG.

Interest expenses for fiscal 2023 include expenses of €0.4 million (2022: €0.6 million) that resulted from compounding provisions for employee retirement benefits and similar obligations.

22. Write Downs on Financial Assets and Short-term Investments

In the fiscal year, a long-term loan to Sartorius Ventures GmbH was written off in the amount of €20.0 million (previous year: €0.0 million).

23. Income Tax Expense

in millions of €	2023	2022
Current income taxes	-2.9	-0.1
Income taxes for the previous years	0.9	0.0
	-2.0	-0.1

24. Non-Periodic Income and Expenses

Non-periodic income and expenses are items that do influence current results, but concern changes in transactions of the past years.

For Sartorius AG, the income to be allocated to the other business years is €1.0 million (2022: €67.3 million). This amount primarily includes income taxes for the previous years. For 2022, the amount primarily includes income from asset sales.

The non-periodic expenses of Sartorius AG totaled €0.7 million (2022: €0.0 million). This primarily concerns subsequent payments due to altered property tax assessments for previous years..

Other Disclosures

Number of Employees (Section 285, No. 7, of the German Commercial Code "HGB")

Sartorius AG does not employ any staff to be disclosed pursuant to Section 285, No. 7, HGB.

Remuneration of the Executive Board and the Supervisory Board (Section 285, No. 9, of HGB)

The remuneration of the Supervisory Board members of Sartorius AG was €1.6 million (2022: €1.0 million).

The total remuneration of the Executive Board members of Sartorius AG was €5.0 million (2022: €5.5 million).

In addition, former members of the Executive Board and their surviving dependents received remuneration of €0.5 million (2022: €0.5 million). A provision of €9.8 million (2022: €9.0 million) was set up to meet retirement benefit obligations for former members of the Executive Board and their surviving dependents.

The main features of the remuneration policy and the disclosures on individual remuneration of the members of the Executive Board and of the Supervisory Board are part of the combined Group Management Report.

In the year under review, 3,374 phantom stock units with a fair value of €1.2 million were paid out according to the grant dates.

Loans were not granted to any members of the Supervisory Board or of the Executive Board in the year under review.

Members of the Executive Board and the Supervisory Board (Section 285, No. 10, of HGB)

The members of the Supervisory Board and of the Executive Board, as well as further disclosures pursuant to Section 285, No. 10, of HGB are listed in the Supplementary Information section.

List of Shareholdings (Section 285, Nos. 11, 11a and 11b of HGB)

A list of the share ownership is annexed in the Supplementary Information section.

The equity and the net profit figures for the individual companies correspond to the IFRS data used to prepare the Group financial statements. For non-consolidated companies, the numbers from the previous year's financial statements were used.

Declaration acc. to Section 161 of the German Stock Corporation Law (AktG) (Section 285, No. 16, of HGB)

The declaration prescribed by Section 161 of the German Stock Corporation Law (AktG) was given on December 7, 2023, and made permanently available to the shareholders of Sartorius AG on the company's website at "www.sartorius.com."

Disclosures on the Auditor's Fees (Section 285, No. 17, of HGB)

The consultation expenses reported under other operating expenses include the fees for services rendered by the auditing company for:

in millions of €	2023	2022
Auditing of the annual financial statements and of the consolidated annual financial statements	-0.8	-0.6
Other attestation services	-0.3	-0.1
Other services	0.0	0.0
	-1.1	-0.7

Relationships with Affiliated Companies (Section 285, No. 21, of HGB)

The following table covers all business transactions with related companies and persons for fiscal 2022:

Affiliated Companies

in millions of €	2023	2022
Financing received	33.9	26.8
Financing provided	1,831.4	2,272.0
Interest income, Income from long-term loans	67.4	23.1
Sales revenue, Other operating income	23.7	19.5
Interest expenses	-5.3	0.0
Other operation expenses	-6.6	-6.1

For information on the remuneration of the Supervisory Board members and of the Executive Board members, please refer to the explanations on the previous page.

Supplementary Report (Section 285, No. 33, of HGB)

On February 7, 2024, Sartorius AG completed the placement of 613,497 preference shares held by the company excluding the subscription rights of existing shareholders. The preference shares were placed at a price of €326.00 per share. Gross proceeds amount to approximately €200 million. The placement preference shares were issued exclusively to institutional investors in the course of a private placement through an accelerated bookbuilding process and will be fully entitled to dividends from January 1, 2023.

The net proceeds from the placement of treasury shares will accelerate the deleveraging of Sartorius Group beyond a strong operating cash flow as well as strengthen the strategic flexibility of the company as a whole.

Independent of the above, Sartorius' French listed subgroup Sartorius Stedim Biotech S.A. also carried out a capital increase on February 7, 2024, where 5,150,215 new shares with a volume of approximately €1.2 billion

were placed in the course of an accelerated bookbuilding process. The Sartorius AG has participated in this capital increase by acquiring 1,716,739 new SSB shares with a total volume of approximately €400 million at a placement price of €233.00. After completion of the capital increase Sartorius AG's stake in Sartorius Stedim Biotech S.A. will amount to approximately 71.5 % of the share capital.

Taking these measures into account, the Group anticipates a reduction of net debt by around €1 billion.

No other material events occurred up to the end of the preparation of these consolidated financial statements.

Proposal for Appropriation of Profit (Section 285, No. 34, of HGB)

The Executive Board and the Supervisory Board will submit a proposal to the Annual Shareholders' Meeting to appropriate the retained profit of €283,012,753.53 for the year ended on December 31, 2023, as follows:

€	
Payment of a dividend of €0.73 per ordinary share	24,987,482.44
Payment of a dividend of €0.74 per preference share	25,756,485.14
Unappropriated profit carried forward	232,268,785.95
	283,012,753.53

Disclosure acc. to Section 160 (1), No. 8, of AktG

As of December 31, 2022, the company had the following information related to shareholdings subject to notification in accordance with Section 160 (1), No. 8, of the German Stock Corporation Law (AktG):

- Christine Franken notified us that she directly or indirectly held 59.25% of the voting rights in the share capital of Sartorius AG on April 1, 2002, including a share of 55.59% in the voting rights that she holds as a member of the community of heirs regarding the estate of Horst Sartorius.
- Dr. Lothar Kappich notified us that he directly or indirectly held 50.09% of the voting rights (18,754,160 voting rights) in the share capital of Sartorius AG on September 8, 2017, including a share of 50.09% in the voting rights (18,754,160 voting rights) that are attributable to him as executor of the estate of Horst Sartorius.
- Karin Sartorius-Herbst notified us that she directly or indirectly held 52.38% of the voting rights (19,609,833 voting rights) in the share capital of Sartorius AG on March 9, 2022, including a share of 50.09% in the voting rights (18,754,160 voting rights) which she and the entities controlled by her Sartorius-Herbst Beteiligungen I GmbH and Sartorius-Herbst Beteiligungen II GmbH hold as members of the community of heirs regarding the estate of Horst Sartorius.
- Alexander Schemann notified us that he directly or indirectly held 50.09% of the voting rights (18,754,160 voting rights) in the share capital of Sartorius AG on March 9, 2022, including a share of 50.09% in the voting rights (18,754,160 voting rights) which LifeScience Holding SCSp, which is controlled by Alexander Schemann – via the chain of subsidiaries beginning with the senior controlling entity Armira Partners Verwaltungs GmbH, Armira Partners GmbH & Co. KG, Armira HC Holding GmbH, LSH Management GP S.à r.l. – holds as a member of the community of heirs regarding the estate of Horst Sartorius.

5. Alice N. Schwartz notified us that she directly or indirectly held 33.28% of the voting rights (3,115,201 voting rights) in the share capital of Sartorius AG on October 1, 2013, including a share of 33.28% in the voting rights (3,115,201 voting rights) which Bio-Rad Laboratories GmbH, which is controlled by Alice N. Schwartz – via the chain of subsidiaries beginning with the senior controlling entity, David Schwartz Non-Exempt Marital Trust, Blue Raven Partners, L.P., Bio-Rad Laboratories, Inc., Bio-Rad Luxembourg S.à r.l., Bio-Rad France Holding SAS – holds as a member of the community of heirs regarding the estate of Horst Sartorius.
6. Ulrike Baro notified us that she directly or indirectly held 0.00% of the voting rights (0 voting rights) in the share capital of Sartorius AG on March 9, 2022 and had dropped below all reportable thresholds in accordance with Section 6 of the German Securities Trading Act.
7. Britta Franken, Julius Franken, Carla Franken and Henri Franken notified us that they directly or indirectly held 0.00% of the voting rights (0 voting rights) in the share capital of Sartorius AG on March 9, 2022 and had dropped below all reportable thresholds in accordance with Section 6 of the German Securities Trading Act.
8. Kai Christian Franken notified us that he directly or indirectly held 0.00% of the voting rights (0 voting rights) in the share capital of Sartorius AG on March 9, 2022 and had dropped below all reportable thresholds in accordance with Section 6 of the German Securities Trading Act.

Göttingen, February 7, 2024

Sartorius Aktiengesellschaft

The Executive Board

Declaration of the Executive Board

We declare to the best of our knowledge that the year-end financial statements for fiscal 2023 present a true and fair view of the actual net worth, financial situation and profitability of the company in accordance with the accounting standards used in preparing these statements. We also certify that the progress of the company's business, including its business performance and its situation, are represented accurately in the Group Management Report in all material respects and present the most important opportunities and risks of the company's future development during the fiscal year.

Göttingen, February 7, 2024

Sartorius Aktiengesellschaft

The Executive Board

Dr. Joachim Kreuzburg

Dr. René Fáber

Dr. Alexandra Gatzemeyer



Independent Auditor's Report

To Sartorius Aktiengesellschaft, Göttingen

Report on the Audit of the Annual Financial Statements and of the Management Report

Opinions

We have audited the annual financial statements of Sartorius Aktiengesellschaft, Göttingen, which comprise the balance sheet as of December 31, 2023, and the income statement for the financial year from January 1 to December 31, 2023, and notes to the financial statements, including the recognition and measurement policies presented therein. In addition, we have audited the management report of the Company and the Group (hereinafter the "management report") of Sartorius Aktiengesellschaft for the financial year from January 1 to December 31, 2023.

In accordance with German legal requirements, we have not audited the content of those components of the management report specified in the "Other Information" section of our auditor's report.

In our opinion, on the basis of the knowledge obtained in the audit,

- the accompanying annual financial statements comply, in all material respects, with the requirements of German commercial law applicable to business corporations and give a true and fair view of the assets, liabilities and financial position of the Company as of December 31, 2023, and of its financial performance for the financial year from January 1 to December 31, 2023, in compliance with German legally required accounting principles, and
- the accompanying management report as a whole provides an appropriate view of the Company's position. In all material respects, this management report is consistent with the annual financial statements, complies with German legal requirements and appropriately presents the opportunities and risks of future development. Our opinion on the management report does not cover the content of those components of the management report specified in the "Other Information" section of the auditor's report.

Pursuant to Section 322 (3) sentence 1 HGB [Handelsgesetzbuch: German Commercial Code], we declare that our audit has not led to any reservations relating to the legal compliance of the annual financial statements and of the management report.

Basis for the Opinions

We conducted our audit of the annual financial statements and of the management report in accordance with Section 317 HGB and the EU Audit Regulation No. 537/2014 (referred to subsequently as "EU Audit Regulation") and in compliance with German Generally Accepted Standards for Financial Statement Audits promulgated by the Institut der Wirtschaftsprüfer [Institute of Public Auditors in Germany] (IDW). Our responsibilities under those requirements and principles are further described in the "Auditor's Responsibilities for the Audit of the Annual Financial Statements and of the Management Report" section of our auditor's report. We are independent of the Company in accordance with the requirements of European law and German commercial and professional law, and we have fulfilled our other German professional responsibilities in accordance with these requirements. In addition, in accordance with Article 10 (2)(f) of the EU Audit Regulation, we declare that we have not provided non-audit services prohibited under Article 5 (1) of the EU Audit Regulation. We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinions on the annual financial statements and on the management report.

Key Audit Matters in the Audit of the Annual Financial Statements

We have determined that there are no key audit matters which need to be reported in our independent auditor's report.

Other Information

Management and/or the Supervisory Board are/is responsible for the other information. The other information comprises the following components of the management report, whose content was not audited:

- the Group's non-financial statement in the thus named section of the management report, and
- the corporate governance statement in the thus named section of the management report.

The other information also includes the remaining parts of the annual report. The other information does not include the annual financial statements, the management report information audited for content and our auditor's report thereon.

Our opinions on the annual financial statements and on the management report do not cover the other information, and consequently we do not express an opinion or any other form of assurance conclusion thereon.

In connection with our audit, our responsibility is to read the other information and, in so doing, to consider whether the other information

- is materially inconsistent with the annual financial statements, with the management report information audited for content or our knowledge obtained in the audit, or
- otherwise appears to be materially misstated.

In accordance with our engagement letter, we conducted a separate assurance engagement of the non-financial statement. Please refer to our assurance report dated February 8, 2024, for information on the nature, scope and findings of this assurance engagement.

Responsibilities of Management and the Supervisory Board for the Annual Financial Statements and the Management Report

Management is responsible for the preparation of the annual financial statements that comply, in all material respects, with the requirements of German commercial law applicable to business corporations, and that the annual financial statements give a true and fair view of the assets, liabilities, financial position and financial performance of the Company in compliance with German legally required accounting principles. In addition, management is responsible for such internal control as they, in accordance with German legally required accounting principles, have determined necessary to enable the preparation of annual financial statements that are free from material misstatement, whether due to fraud (i.e., fraudulent financial reporting and misappropriation of assets) or error.

In preparing the annual financial statements, management is responsible for assessing the Company's ability to continue as a going concern. They also have the responsibility for disclosing, as applicable, matters related to going concern. In addition, they are responsible for financial reporting based on the going-concern basis of accounting, provided no actual or legal circumstances conflict therewith.

Furthermore, management is responsible for the preparation of the management report that as a whole provides an appropriate view of the Company's position and is, in all material respects, consistent with the annual financial statements, complies with German legal requirements, and appropriately presents the opportunities and risks of future development. In addition, management is responsible for such arrangements and measures (systems) as they have considered necessary to enable the preparation of a management report that is in accordance with the applicable German legal requirements, and to be able to provide sufficient appropriate evidence for the assertions in the management report.

The Supervisory Board is responsible for overseeing the Company's financial reporting process for the preparation of the annual financial statements and of the management report.

Auditor's Responsibilities for the Audit of the Annual Financial Statements and of the Management Report

Our objectives are to obtain reasonable assurance about whether the annual financial statements as a whole are free from material misstatement, whether due to fraud or error, and whether the management report as a whole provides an appropriate view of the Company's position and, in all material respects, is consistent with the annual financial statements and the knowledge obtained in the audit, complies with the German legal requirements and appropriately presents the opportunities and risks of future development, as well as to issue an auditor's report that includes our opinions on the annual financial statements and on the management report.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Section 317 HGB and the EU Audit Regulation and in compliance with German Generally Accepted Standards for Financial Statement Audits promulgated by the Institut der Wirtschaftsprüfer (IDW) will always detect a material misstatement. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial statements and this management report.

We exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual financial statements and of the management report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinions. The risk of not detecting a material misstatement resulting from fraud is higher than the risk of not detecting a material misstatement resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
- Obtain an understanding of internal control relevant to the audit of the annual financial statements and of arrangements and measures (systems) relevant to the audit of the management report in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of these systems.
- Evaluate the appropriateness of accounting policies used by management and the reasonableness of estimates made by management and related disclosures.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in the auditor's report to the related disclosures in the annual financial statements and in the management report or, if such disclosures are inadequate, to modify our respective opinions. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to be able to continue as a going concern.
- Evaluate the overall presentation, structure and content of the annual financial statements, including the disclosures, and whether the annual financial statements present the underlying transactions and events in a manner that the annual financial statements give a true and fair view of the assets, liabilities, financial position and financial performance of the Company in compliance with German legally required accounting principles.
- Evaluate the consistency of the management report with the annual financial statements, its conformity with [German] law and the view of the Company's position it provides.
- Perform audit procedures on the prospective information presented by management in the management report. On the basis of sufficient appropriate audit evidence we evaluate, in particular, the significant assumptions used by management as a basis for the prospective information, and evaluate the proper derivation of the prospective information from these assumptions. We do not express a separate opinion on the prospective information and on the assumptions used as a basis. There is a substantial unavoidable risk that future events will differ materially from the prospective information.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with the relevant independence requirements, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, the actions taken or safeguards applied to eliminate independence threats.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the annual financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter.

Other Legal and Regulatory Requirements

Report on the Assurance on the Electronic Rendering of the Annual Financial Statements and the Management Report Prepared for Publication Purposes in Accordance with Section 317 (3a) HGB

We have performed assurance work in accordance with Section 317 (3a) HGB to obtain reasonable assurance about whether the rendering of the annual financial statements and the management report (hereinafter the "ESEF documents") contained in the electronic file "sartoriusagea.zip" (SHA256 hash value: fe58eaf799d143ec915d6b3b706f969106d00435b585e83cf879f9c28fdb10c4) made available and prepared for publication purposes complies in all material respects with the requirements of Section 328 (1) HGB for the electronic reporting format ("ESEF format"). In accordance with German legal requirements, this assurance work extends only to the conversion of the information contained in the annual financial statements and the management report into the ESEF format and therefore relates neither to the information contained within these renderings nor to any other information contained in the file identified above.

In our opinion, the rendering of the annual financial statements and the management report contained in the electronic file made available identified above and prepared for publication purposes complies in all material respects with the requirements of Section 328 (1) HGB for the electronic reporting format. Beyond this assurance opinion and our audit opinion on the accompanying annual financial statements and the accompanying management report for the financial year from January 1 to December 31, 2023, contained in the "Report on the Audit of the Annual Financial Statements and of the Management Report" above, we do not express any assurance opinion on the information contained within these renderings or on the other information contained in the file identified above.

We conducted our assurance work on the rendering of the annual financial statements and the management report, contained in the file made available and identified above in accordance with Section 317 (3a) HGB and the IDW Assurance Standard: Assurance Work on the Electronic Rendering of Financial Statements and Management Reports Prepared for Publication Purposes in Accordance with Section 317 (3a) HGB (IDW AsS 410 (06.2022)) and the International Standard on Assurance Engagements 3000 (Revised). Our responsibility in accordance therewith is further described below. Our audit firm applies the IDW Standard on Quality Management 1: Requirements for Quality Management in Audit Firms (IDW QMS 1) (09.2022).

The Company's management is responsible for the preparation of the ESEF documents including the electronic renderings of the annual financial statements and the management report in accordance with Section 328 (1) sentence 4 item 1 HGB.

In addition, the Company's management is responsible for such internal control as they have considered necessary to enable the preparation of ESEF documents that are free from material intentional or unintentional non-compliance with the requirements of Section 328 (1) HGB for the electronic reporting format.

The Supervisory Board is responsible for overseeing the process of preparing the ESEF documents as part of the financial reporting process.

Our objective is to obtain reasonable assurance about whether the ESEF documents are free from material intentional or unintentional non-compliance with the requirements of Section 328 (1) HGB. We exercise professional judgment and maintain professional skepticism throughout the assurance work. We also:

- Identify and assess the risks of material intentional or unintentional non-compliance with the requirements of Section 328 (1) HGB, design and perform assurance procedures responsive to those risks, and obtain assurance evidence that is sufficient and appropriate to provide a basis for our assurance opinion.
- Obtain an understanding of internal control relevant to the assurance on the ESEF documents in order to design assurance procedures that are appropriate in the circumstances, but not for the purpose of expressing an assurance opinion on the effectiveness of these controls.
- Evaluate the technical validity of the ESEF documents, i.e. whether the file made available, containing the ESEF documents meets the requirements of Commission Delegated Regulation (EU) 2019/815, as amended as of the reporting date, on the technical specification for this electronic file.
- Evaluate whether the ESEF documents provide an XHTML rendering with content equivalent to the audited annual financial statements and the audited management report.

Further information pursuant to Article 10 of the EU Audit Regulation

We were elected as auditor at the Annual General Meeting on March 29, 2023. We were engaged by the Supervisory Board on October 11, 2023. We have been the auditor of Sartorius Aktiengesellschaft without interruption since financial year 2015.

We declare that the opinions expressed in this auditor's report are consistent with the additional report to the Audit Committee pursuant to Article 11 of the EU Audit Regulation (long-form audit report).

In addition to the annual financial statements, we audited the consolidated financial statements of Sartorius Aktiengesellschaft and performed various audits of annual financial statements at subsidiaries. In addition, reviews of interim financial statements were performed. Furthermore, contractually agreed audits were performed, such as the review of the Group's non-financial statement and the examination of the remuneration report and the issuing of a comfort letter.

Other Matter – Use of the Auditor's Report

Our auditor's report must always be read together with the audited annual financial statements and the audited management report as well as the examined ESEF documents. The annual financial statements and the management report converted into ESEF format – including the versions to be entered in the German Company Register [Unternehmensregister] – are merely electronic renderings of the audited annual financial statements and the audited management report and do not take their place. In particular, the ESEF report and our assurance opinion contained therein are to be used solely together with the examined ESEF documents provided in electronic form.

Note on the Supplementary Audit

We issue this independent auditor's report on the annual financial statements and the management report as well as for the electronic reproduction of the annual financial statements and management report presented to us for assurance for the first time, contained in the file "sartoriusagea.zip" (SHA256 hash value: fe58eaf799d143ec915d6b3b706f969106d00435b585e83cf879f9c28fdb10c4) and prepared for publication purposes, based on our audit duly completed on February 8, 2024, and our supplementary audit completed on February 14, 2024, which relates to the first-time submission of the ESEF documents.

German Public Auditor Responsible for the Engagement

The German Public Auditor responsible for the engagement is Haiko Schmidt.

Hanover, February 8, 2024/limited to the
assurance of the ESEF documents specified in the information on the supplementary audit:
February 14, 2024

KPMG AG
Wirtschaftsprüfungsgesellschaft
[Original German version signed by:]

Schmidt
Wirtschaftsprüfer
[German Public Auditor]

Hartke
Wirtschaftsprüferin
[German Public Auditor]

Development of Fixed Assets

in millions €	Acquisition and production costs				Dec. 31, 2023
	Jan. 1, 2023	Additions	Transfers	Disposals	
I. Intangible assets					
Purchased concessions, industrial property rights and similar rights as well as licenses for such rights and assets	27.7	0.0	0.0	0.0	27.7
II. Property, plant and equipment					
1. Land and leasehold rights and improvements, including buildings on third-party land	149.7	0.0	0.1	0.1	149.7
2. Factory and office equipment and other equipment	4.1	0.1	0.1	0.0	4.3
3. Payments on account and construction in progress	0.2	0.9	-0.2	0.0	0.9
	154.0	1.0	0.0	0.1	154.9
III. Financial assets					
1. Shares in affiliated companies	439.2	0.0	0.0	0.0	439.2
2. Loans to affiliated companies	2,158.9	330.0	0.0	815.4	1,673.5
3. Investments (participating interest)	0.0	0.0	0.0	0.0	0.0
4. Other loans	4.4	0.7	0.0	0.0	5.1
	2,602.5	330.7	0.0	815.4	2,117.8
	2,784.2	331.7	0.0	815.5	2,300.4

in millions €	Accumulated depreciation and impairment losses					Book values		
	Jan. 1, 2023	Depreciation and impairment losses in fiscal 2023	Transfers	Disposals	Reversals of impairment	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
I. Intangible assets								
Purchased concessions, industrial property rights and similar rights as well as licenses for such rights and assets	14.8	5.5	0.0	0.0	0.0	20.3	7.4	12.9
II. Property, plant and equipment								
1. Land and leasehold rights and improvements, including buildings on third-party land	19.6	4.5	0.0	0.0	0.0	24.1	125.6	130.1
2. Factory and office, equipment and other equipment	1.4	0.4	0.0	0.0	0.0	1.8	2.5	2.7
3. Payments on account and construction in progress	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.2
	21.0	4.9	0.0	0.0	0.0	25.9	129.0	133.0
III. Financial assets								
1. Shares in affiliated companies	0.0	0.0	0.0	0.0	0.0	0.0	439.2	439.2
2. Loans to affiliated companies	0.0	20.0	0.0	0.0	0.0	20.0	1,653.5	2,158.9
3. Investments (participating interest)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
4. Other loans	0.0	0.0	0.0	0.0	0.0	0.0	5.1	4.4
	0.0	20.0	0.0	0.0	0.0	20.0	2,097.8	2,602.5
	35.8	30.4	0.0	0.0	0.0	66.2	2,234.2	2,748.4

Share Ownership

	Ownership	Equity at Dec. 31, 2023	Net profit at Dec. 31, 2023
	in %	in millions €	in millions €
Sartorius Stedim Biotech S.A., Aubagne, France, along with its subsidiaries:	73.6	234.5	100.9
EMEA			
Sartorius Stedim Belgium SA, Woluwe-Saint-Lambert, Belgium ¹	100.0	5.5	4.6
ACCESSIA PHARMA S.A., Herstal, Belgium ¹	100.0	-2.1	-0.3
XpressBioX SRL, Herstal, Belgium ¹	100.0	8.9	-0.2
XPRESS BIOLOGICS S.A., Herstal, Belgium ¹	100.0	-0.5	-2.1
Sartorius Xell GmbH, Schloß Holte-Stukenbrock, Germany ^{1,4}	100.0	14.3	-3.0
Distribo GmbH, Göttingen, Germany ^{1,3}	26.0	3.2	0.5
Sartorius Stedim Biotech GmbH, Göttingen, Germany ¹	100.0	1,514.4	358.2
Sartorius Stedim Plastics GmbH, Göttingen, Germany ^{1,4}	100.0	0.7	-0.4
Sartorius Stedim North America Holding GmbH, Göttingen, Germany ^{1,4}	100.0	41.9	0.0
Sartorius Stedim Systems GmbH, Guxhagen, Germany ^{1,4}	100.0	47.8	5.4
Sartorius CellGenix GmbH, Freiburg im Breisgau, Germany ¹	76.0	59.8	11.7
Metreon Bioproducts GmbH, Freiburg im Breisgau, Germany ^{1,3}	100.0	0.0	0.0
Sartorius Stedim Cellca GmbH, Ulm, Germany ^{1,4}	100.0	7.9	-2.7
Sartorius Stedim Nordic oy, Helsinki, Finland ¹	100.0	2.7	2.3
Sartorius Stedim FMT S.A.S., Aubagne, France ¹	100.0	140.9	5.9
Sartorius Stedim France S.A.S., Aubagne, France ¹	100.0	11.2	8.3
Sartorius Stedim Chromatography Resins S.A.S., Cergy, France ¹	100.0	7.1	1.1
PolygenX 2 S.A.S., Illkirch-Graffenstaden, France ¹	100.0	108.4	-0.3
PolygenX A S.A.S., Illkirch-Graffenstaden, France ¹	100.0	449.7	1.2
PolygenX D S.A.S., Paris, France ¹	100.0	352.1	-4.6
POLYPLUS-TRANSFECTION S.A., Illkirch-Graffenstaden, France ¹	100.0	86.9	13.3
Sartorius Stedim Aseptics S.A.S., Lourdes, France ¹	100.0	9.0	3.7
BIO ELPIDA S.A.S., Saint-Priest, France ¹	100.0	-5.4	-0.6
Sartorius Chromatography Equipment S.A.S., Pompey, France ¹	100.0	37.4	-2.1
Sartorius Stedim Ireland Ltd., Dublin, Ireland ¹	100.0	15.9	15.0
Biological Industries Israel Beit Haemek Ltd., Kibbutz Beit Haemek, Israel ¹	100.0	33.1	-4.2
Sartorius Stedim Italy S.p.A., Florence, Italy ¹	100.0	18.0	3.9
Sartorius Stedim Netherlands B.V., Amersfoort, Netherlands ¹	100.0	1.8	1.8
Sartorius Stedim Austria GmbH, Vienna, Austria ¹	100.0	3.3	2.0
Sartorius Stedim Poland Sp. z o.o., Kostrzyn, Poland ¹	100.0	2.0	1.4
LLC Sartorius Stedim RUS, St. Petersburg, Russia ¹	100.0	12.6	1.6
Sartorius Stedim Data Analytics AB, Umeå, Sweden ¹	100.0	31.3	10.1
Sartorius Stedim Switzerland AG, Tagelswangen, Switzerland ¹	100.0	24.7	19.6
Sartorius BIA Separations, separacijske tehnologije, d.o.o., Ajdovščina, Slovenia ¹	100.0	39.4	-5.5
Sartorius Stedim Spain S.A., Madrid, Spain ¹	100.0	11.3	4.4
Sartorius Stedim Bioprocess S.A.R.L., M'Hamdia, Tunisia ¹	100.0	15.6	3.8
Sartonet Seperasyon Teknolojileri Anonim Şirketi, Istanbul, Türkiye ¹	100.0	10.6	4.0

	Ownership	Equity at Dec. 31, 2023	Net profit at Dec. 31, 2023
	in %	in millions €	in millions €
Sartorius Stedim Hungária Kft., Budapest, Hungary ¹	100.0	2.0	0.7
Sartorius Stedim BioOutsource Ltd., Glasgow, U.K. ¹	100.0	-7.9	-3.8
Sartorius Stedim UK Ltd., Epsom, U.K. ¹	100.0	8.8	7.6
Sartorius Stedim Lab Ltd., Stonehouse, U.K. ¹	100.0	25.9	4.0
Sartorius Stedim Chromatography Systems Ltd., Royston, U.K. ¹	100.0	39.2	-0.9
TAP Biosystems Group Ltd., Royston, U.K. ¹	100.0	1.9	115.0
The Automation Partnership Cambridge Ltd., Royston, U.K. ¹	100.0	73.6	62.3
Albumedix Ltd., Nottingham, U.K. ¹	100.0	36.1	12.8
Virocell Biologics Ltd., London, U.K. ^{1,3}	30.0	10.4	-9.9
The Americas			
Sartorius Stedim Filters Inc., Yauco, Puerto Rico ¹	100.0	332.6	25.6
WaterSep BioSeparations LLC, Boston, Massachusetts, USA ¹	100.0	-1.5	-3.5
Sartorius DC BPS Americas, Inc., Dover, Delaware, USA ¹	100.0	-1.7	-1.7
Sartorius Stedim North America, Inc., Dover, Delaware, USA ¹	100.0	230.0	19.6
CellGenix Inc., Wilmington, Delaware, USA ^{1,3}	100.0	0.2	0.0
Polyplus Transfection Inc., Wilmington, Delaware, USA ¹	100.0	10.3	2.2
Asia Pacific			
Sartorius Stedim Australia Pty. Ltd., Dandenong South, Victoria, Australia ¹	100.0	2.8	0.1
Sartorius Stedim Biotech (Beijing) Co. Ltd., Beijing, China ¹	100.0	-3.3	1.0
Biowire Shanghai Ltd., Shanghai, China ^{1,3}	100.0	0.8	0.0
Sartorius Stedim (Shanghai) Trading Co. Ltd., Shanghai, China ¹	100.0	41.9	-5.2
Kobmast Ltd., Central Hong Kong, Hong Kong ^{1,3}	100.0	0.4	0.1
Sartorius Stedim India Pvt. Ltd., Bangalore, India ¹	100.0	25.9	-1.6
Sartorius Stedim Japan K.K., Tokyo, Japan ¹	100.0	10.9	3.2
Sartorius Stedim Malaysia Sdn. Bhd., Kuala Lumpur, Malaysia ¹	100.0	0.7	0.2
Polyplus Transfection Pte. Ltd., Singapore, Singapore ^{1,3}	100.0	-0.6	-0.5
Sartorius Stedim Singapore Pte. Ltd., Singapore, Singapore ¹	100.0	27.9	5.0
Sartorius Korea Biotech Co. Ltd., Seoul, South Korea ¹	79.0	44.1	8.7
Sartorius Korea Operations LLC, Seoul, South Korea ¹	100.0	80.0	-2.0
Sartorius Stedim Taiwan Inc., New Taipei City, Taiwan ¹	100.0	2.4	0.1
EMEA			
Sartorius Belgium N.V., Woluwe-Saint-Lambert, Belgium ²	100.0	1.7	0.6
Curexsys GmbH, Göttingen, Germany ^{2,3}	24.3	3.5	-7.0
Sartorius Weighing Technology GmbH, Göttingen, Germany ^{2,4}	100.0	45.0	0.0
Sartorius Corporate Administration GmbH, Göttingen, Germany ⁴	100.0	0.2	1.7
SI Weende-Verwaltungs-GmbH, Göttingen, Germany	100.0	0.0	0.0
SIV Weende GmbH & Co. KG, Göttingen, Germany	100.0	-6.4	-2.6
SI Grone 1-Verwaltungs-GmbH, Göttingen, Germany ²	100.0	0.0	0.0
SIV Grone 1 GmbH & Co. KG, Göttingen, Germany ²	100.0	2.0	0.1
SIV Grone 2 GmbH, Göttingen, Germany	100.0	0.0	0.0
SWT Treuhand GmbH, Göttingen, Germany ²	100.0	0.0	0.0
Sartorius Ventures GmbH, Göttingen, Germany	100.0	-19.1	-15.4
LabTwin GmbH, Berlin, Germany ^{2,3}	94.0	-4.1	-6.4

	Ownership	Equity at Dec. 31, 2023	Net profit at Dec. 31, 2023
	in %	in millions €	in millions €
Life Science Factory GmbH, Göttingen, Germany ^{2,3}	100.0	0.0	0.0
Life Science Factory Management GmbH, Göttingen, Germany ^{2,4}	100.0	0.0	0.0
Life Science Valley GmbH, Göttingen, Germany ^{2,3}	80.0	0.0	-0.1
Life Science Valley Ventures Management GmbH, Göttingen, Germany ^{2,3}	49.0	0.0	0.0
Life Science Valley Ventures GP GmbH, Göttingen, Germany ^{2,3}	100.0	0.0	0.0
Life Science Valley Carry I GmbH & Co. KG, Göttingen, Germany ^{2,3}	100.0	0.0	0.0
Life Science Valley Wachstumsfonds I GmbH & Co. KG, Göttingen, Germany ^{2,3}	35.8	-0.2	-0.2
Sartorius Immobilien Jena GmbH & Co. KG, Göttingen, Germany	100.0	0.0	0.0
Sartorius Lab Holding GmbH, Göttingen, Germany ⁴	100.0	-62.1	-31.2
Sartorius Lab Instruments GmbH & Co. KG, Göttingen, Germany ²	100.0	-10.7	9.4
ALS Automated Lab Solutions GmbH, Jena, Germany ²	62.5	7.4	2.3
Sartorius Biohit Liquid Handling Oy, Helsinki, Finland ²	100.0	7.3	-5.2
Sartorius Nordic oy, Helsinki, Finland ²	100.0	0.5	0.4
Sartorius France S.A.S., Dourdan, France ²	100.0	2.1	0.9
Sartorius Ireland Ltd., Dublin, Ireland ²	100.0	1.2	0.2
Sartorius Israel Ltd., Kibbutz Beit Haemek, Israel ²	100.0	3.5	0.6
Sartorius Italy S.r.l., Florence, Italy ²	100.0	2.7	0.8
Sartorius Netherlands B.V., Amersfoort, Netherlands ²	100.0	0.8	0.4
Sartorius Finance B.V., Amsterdam, Netherlands	100.0	0.1	0.0
Sartorius Austria GmbH, Vienna, Austria ²	100.0	3.3	0.4
Sartorius Poland Sp. z o.o., Kostrzyn, Poland ²	100.0	0.7	0.4
LLC Sartogom, St. Petersburg, Russia ²	100.0	0.9	0.0
LLC Sartorius RUS, St. Petersburg, Russia ²	100.0	5.3	1.4
BICO Group AB, Gothenburg, Sweden ^{2,3}	10.1	625.8	-75.4
Sartorius Spain S.A., Madrid, Spain ²	100.0	0.5	0.3
Sartorius South Africa (Pty) Ltd., Midrand, South Africa ²	100.0	0.7	0.2
Sartorius Hungária Kft., Budapest, Hungary ²	100.0	1.1	0.1
EssenBioScience Ltd., Royston, U.K. ²	100.0	7.0	0.3
Sartorius UK Ltd., Epsom, U.K. ²	100.0	4.6	2.1
SPARTA Biodiscovery Ltd., London, U.K. ^{2,3}	25.0	1.3	-0.3
The Americas			
Sartorius Argentina S.A., Buenos Aires, Argentina ²	100.0	-6.3	-18.1
Sartorius do Brasil Ltda., São Paulo, Brazil ²	100.0	-1.4	0.4
Sartorius Canada Inc., Oakville, Canada ²	100.0	0.3	0.0
Sartorius de México S.A. de C.V., Tepotzotlán, Mexico ²	100.0	5.2	0.8
Sartorius BioAnalytical Instruments Inc., Dover, Delaware, USA ²	100.0	71.6	-21.6
Sartorius DC LPS Americas, Inc., Dover, Delaware, USA ¹	100.0	-0.5	-0.5
Sartorius North America, Inc., Dover, Delaware, USA ²	100.0	545.0	130.1
Sartorius Corporation, Dover, Delaware, USA ²	100.0	29.6	12.6
Asia Pacific			
Sartorius Australia Pty. Ltd., Dandenong South, Victoria, Australia ²	100.0	1.3	0.5
Sartorius Scientific Instruments (Beijing) Co. Ltd., Beijing, China ²	100.0	32.5	1.6
Sartorius ForteBio (Shanghai) Co. Ltd., Shanghai, China ²	100.0	17.3	1.1

	Ownership	Equity at Dec. 31, 2023	Net profit at Dec. 31, 2023
	in %	in millions €	in millions €
Sartorius Lab (Shanghai) Trading Co., Ltd., Shanghai, China ²	100.0	1.1	0.1
Sartorius (Shanghai) Enterprise Management Co., Ltd., Shanghai, China ²	100.0	3.4	0.1
Sartorius (Shanghai) Trading Co. Ltd., Shanghai, China ²	100.0	1.7	0.8
Sartorius Hong Kong Ltd., Kowloon, Hong Kong ²	100.0	3.0	0.3
Sartorius India Pvt. Ltd., Bangalore, India ²	100.0	3.1	1.3
Sartorius Japan K.K., Tokyo, Japan ²	100.0	4.7	-0.1
Sartorius Malaysia Sdn. Bhd., Kuala Lumpur, Malaysia ²	100.0	0.9	0.0
Sartorius Singapore Pte. Ltd., Singapore, Singapore ²	100.0	1.0	0.0
Sartorius Korea LLC, Seoul, South Korea ²	100.0	11.5	1.0
Sartorius (Thailand) Co. Ltd., Bangkok, Thailand ²	32.7	0.2	0.5
Sartorius Vietnam Co. Ltd., Ho Chi Minh City, Vietnam ²	100.0	0.4	-0.1

1 These companies are indirectly held by Sartorius Stedim Biotech S.A., France.

2 These companies are indirectly held.

3 As the financial statements of these companies were not available at the time our consolidated financial statements were prepared, the information from the annual financial statements of 2022 was considered.

4 Profit and loss transfer agreements exist for these companies.

Executive Board and Supervisory Board

During Fiscal 2023

Executive Board

Dr. Joachim Kreuzburg

Dipl.-Ingenieur (Graduate Engineer)

CEO and Chairman

Executive for Labor Relations

Corporate Strategy, Human Resources, Corporate Research, Legal Affairs & Compliance, Communications and Sustainability

Interim lead of Finance, Information Technology, Data Management, Corporate Sourcing until March 31, 2024

Born April 22, 1965

Resident of Göttingen, Germany

Member since November 11, 2002

“Sprecher” (Spokesman) from May 1, 2003, to November 10, 2005

Chairman since November 11, 2005

Appointed until November 10, 2025

Dr. René Fáber

Dipl.-Chemiker (Graduate Chemical Engineer)

Bioprocess Solutions Division

Born July 18, 1975

Resident of Göttingen, Germany

Member since January 1, 2019

Appointed until December 31, 2026

Dr. Alexandra Gatzemeyer

Ph.D. in Chemistry

Lab Products & Services Division

Born July 8, 1979

Resident of Bodenrode-Westhausen, Germany

Member since May 1, 2023

Appointed until April 30, 2026

Exited during Fiscal 2023:

Rainer Lehmann

Dipl.-Kaufmann (Graduate in Business Administration)
Finance, IT and Business Processes
Born March 2, 1975
Resident of Brightwaters, New York, USA
Member from March 1, 2017 until October 31, 2023

John Gerard Mackay

B.Sc. Honors Degree in Biochemistry
Master of Education
Lab Products & Services Division
Born May 11, 1962
Resident of Glasgow, Scotland, UK
Member from January 1, 2019 until June 15, 2023

Supervisory Board

Dr. Lothar Kappich

Dipl.-Ökonom (Graduate Economist)
Chairman
Freelance Consultant, formerly Managing Director of ECE Projektmanagement GmbH & Co. KG
in Hamburg, Germany
Resident of Hamburg, Germany

Manfred Zaffke

Dipl.-Volkswirt (Graduate Political Economist)
Vice Chairman
Project Secretary responsible for special tasks at the German Metalworkers' Union (IG Metall) branch office of
the southern Lower Saxony/Harz region in Northeim, Germany
Resident of Osterode am Harz, Germany

Annette Becker

Personalfachkauffrau (HR Specialist)
Chairwoman of the Employees' Council of Sartorius Corporate Administration GmbH
in Göttingen, Germany
Vice Chairwoman of the Group Employees' Council of Sartorius AG in Göttingen, Germany
Resident of Gleichen, Germany

Professor David Raymond Ebsworth, Ph.D.

B.Sc. in Chemistry and German; Ph.D. in Comparative Industrial Relations
Consultant, especially in the Healthcare and Financial Investment Industry
Resident of Overath, Germany

Dr. Daniela Favoccia

Attorney and Partner of the Hengeler Mueller partnership of lawyers in Frankfurt am Main, Germany
Resident of Frankfurt am Main, Germany

Petra Kirchhoff

Dipl.-Volkswirtin (Graduate Political Economist)
Head of Corporate Communications and Investor Relations
Sartorius Corporate Administration GmbH in Göttingen, Germany
Resident of Göttingen, Germany

Dietmar Müller

Betriebswirt (VWA Göttingen) (Business Economist)
Chairman of the Employees' Council of Sartorius Stedim Biotech GmbH in Göttingen, Germany
Chairman of the Group Employees' Council of Sartorius AG in Göttingen, Germany
Resident of Gleichen, Germany

Ilke Hildegard Panzer

M.Sc. in Engineering, Computer and Systems Engineering
Freelance Consultant in the Healthcare Innovation Industry
Resident of Fredonia, Wisconsin, USA

Frank Riemensperger

Dipl.-Informatiker (Graduate Degree in Computer Science)
Founder and Managing Director of 440.digital GmbH in Dietzenbach, Germany
Consultant and Investor in Digital Companies
Resident of Dietzenbach, Germany

Hermann Jens Ritzau

Chairman of the Employees' Council of Sartorius Lab Instruments GmbH & Co. KG in Göttingen, Germany
Member of the Group Employees' Council of Sartorius AG in Göttingen, Germany
Resident of Katlenburg-Lindau, Germany

Prof. Dr. Klaus Rüdiger Trützschler

Dipl.-Wirtschaftsmathematiker (Graduate Business Mathematician)
and Dipl.-Mathematiker (Graduate Mathematician)
Freelance Business Consultant
Resident of Essen, Germany

Sabrina Wirth

B.A. in Social Science
Political Secretary for Organizational Policy in the District Management of the German Metalworkers' Union (IG Metall) District of Lower Saxony and Saxony-Anhalt in Hanover, Germany
Resident of Nienburg/Weser, Germany

Committees of the Supervisory Board

Executive Task Committee

Dr. Lothar Kappich (Chairman)
Annette Becker
Prof. Dr. Klaus Rüdiger Trützscher
Manfred Zaffke

Audit Committee

Prof. Dr. Klaus Rüdiger Trützscher (Chairman)
Dr. Lothar Kappich
Dietmar Müller
Manfred Zaffke

Conciliation Committee

Dr. Lothar Kappich (Chairman)
Annette Becker
Prof. Dr. Klaus Rüdiger Trützscher
Manfred Zaffke

Nomination Committee

Dr. Lothar Kappich (Chairman)
Dr. Daniela Favoccia
Prof. Dr. Klaus Rüdiger Trützscher

Positions Held by the Members of the Executive Board during Fiscal 2023

Dr. Joachim Kreuzburg

Positions held within the Group:

On the Conseil d'Administration (Board of Directors) of:

- Sartorius Stedim Biotech S.A.¹, France, Chairman

On the Supervisory Board of:

- Sartorius Corporate Administration GmbH, Germany, Chairman (since November 1, 2023)

On the Beirat (Advisory Board) of:

- LabTwin GmbH, Germany, Chairman

On the Board of Directors of:

- Sartorius North America, Inc., USA, Chairman

External positions:

On the Supervisory Board of:

- Carl Zeiss AG, Germany

On the Verwaltungsrat (Administrative Board) of:

- Ottobock Management SE, Germany

On the Wirtschaftsbeirat (Economic Advisory Board) of:

- Norddeutsche Landesbank, Germany (until December 31, 2023)

Dr. René Fáber

Positions held within the Group:

On the Conseil d'Administration (Board of Directors) of:

- Sartorius Stedim Biotech S.A.¹, France (Directeur Général)

On the Supervisory Board of:

- Sartorius Stedim Biotech GmbH, Germany, Chairman

On the Beirat (Advisory Board) of:

- Sartorius CellGenix GmbH, Germany, Chairman

¹ publicly listed

On the Board of Directors of:

- Sartorius Stedim (Shanghai) Trading Co., Ltd., China
- Sartorius Stedim Biotech (Beijing) Co., Ltd., China, Vice Chairman (since July 25, 2023)
- Albumedix Ltd., UK
- Sartorius Stedim BioOutsource Ltd., Scotland, UK (since December 18, 2023)
- Sartorius Korea Biotech LLC, South Korea
- Sartorius Korea Operations LLC, South Korea
- Sartorius Stedim Japan K.K., Japan (until March 26, 2023)
- Sartorius Stedim North America Inc., USA (since November 1, 2023)

On the Comité Exécutif (Executive Committee) of:

- Sartorius Stedim FMT S.A.S., France, Chairman

On the Advisory Board of:

- Sartorius BIA Separations d.o.o., Slovenia, Chairman

External positions:

On the Beirat (Advisory Board) of:

- Curexsys GmbH, Germany

Dr. Alexandra Gatzemeyer¹

Positions held within the Group:

On the Supervisory Board of:

- Sartorius Corporate Administration GmbH, Germany, Vice Chairwoman

On the Board of Directors of:

- Sartorius BioAnalytical Instruments, Inc., USA (since October 1, 2023)
- Sartorius Corporation, USA (since November 1, 2023)
- Sartorius Biohit Liquid Handling Oy, Finland (since October 1, 2023)
- Sartorius Scientific Instruments (Beijing) Co., Ltd., China, Vice Chairwoman (since July 25, 2023)
- Sartorius ForteBio (Shanghai) Co., Ltd., China (since May 10, 2023)
- Sartorius Lab (Shanghai) Trading Co., Ltd., China (since July 4, 2023)
- Sartorius (Shanghai) Trading Co., Ltd., China (since September 8, 2023)
- Sartorius Korea LLC, South Korea (since October 25, 2023)
- Biological Industries Israel Beit Haemek Ltd., Israel (until December 7, 2023)

On the Comité Exécutif (Executive Committee) of:

- Sartorius France S.A.S., France, Chairwoman

External positions:

None

¹ The information on mandates relate to the period of membership of the Executive Board during Fiscal 2023.

Exited during Fiscal 2023:

Rainer Lehmann¹

Positions held within the Group:

On the Supervisory Board of:

- Sartorius Corporate Administration GmbH, Germany, Chairman (since April 1, 2023)

On the Board of Directors of:

- Sartorius Corporation, USA
- Sartorius North America, Inc., USA
- Sartorius Stedim North America Inc., USA
- Sartorius BioAnalytical Instruments, Inc., USA
- Sartorius DC BPS Americas, Inc., USA (since February 2, 2023)
- Sartorius DC LPS Americas, Inc., USA (since February 2, 2023)
- Sartorius Stedim Filters, Inc., Puerto Rico

External positions:

On the Unternehmerbeirat (Employers' Advisory Board) of:

- Gothaer Versicherungsbank VVaG, Germany

On the Regionalbeirat (Regional Advisory Board) of:

- Commerzbank AG², Germany

John Gerard Mackay¹

Positions held within the Group:

On the Board of Directors of:

- Sartorius BioAnalytical Instruments, Inc., USA
- Sartorius Biohit Liquid Handling Oy, Finland
- Sartorius Stedim BioOutsource Ltd., Scotland, UK
- Sartorius Scientific Instruments (Beijing) Co., Ltd., China, Vice Chairman
- Sartorius Hong Kong Ltd., China (until May 16, 2023)
- Sartorius ForteBio (Shanghai) Co., Ltd., China (until May 9, 2023)
- Sartorius (Shanghai) Trading Co., Ltd., China
- Sartorius Japan K.K., Japan (until March 22, 2023)
- Sartorius Korea LLC, South Korea

External positions:

On the Board of Directors of:

BICO Group AB (publ)², Sweden (since May 11, 2023)

¹ The information on mandates relate to the period of membership of the Executive Board during Fiscal 2023.

² publicly listed

Positions Held by the Members of the Supervisory Board during Fiscal 2023

Dr. Lothar Kappich

Positions held within the Group:

On the Conseil d'Administration (Board of Directors) of:

- Sartorius Stedim Biotech S.A.¹, France

External positions:

None

Manfred Zaffke

Positions held within the Group:

None

External positions:

On the Supervisory Board of:

- Demag Cranes & Components GmbH, Germany
- Konecranes Holding GmbH, Germany

Annette Becker

Positions held within the Group:

None

External positions:

On the Verwaltungsrat (Administrative Board) of:

- BKK Technoform, Germany (since September 5, 2023)

Professor David Raymond Ebsworth, Ph.D.

Positions held within the Group:

None

External positions:

On the Board of Directors of:

- Verona Pharma plc¹, UK, Chairman
- Actimed Therapeutics Ltd., UK, Chairman
- Kyowa Kirin International plc, UK, Chairman
- Interpharma Investments Ltd., British Virgin Islands (until March 31, 2023)

On the Supervisory Board of:

- Synlab AG¹, Germany, Chairman

On the Verwaltungsrat (Administrative Board) of:

- Opterion Health AG, Switzerland, Chairman

¹ publicly listed

Dr. Daniela Favoccia

None

Petra Kirchhoff

Positions held within the Group:
None

External positions:

On the Stock Exchange Council (Börsenrat) of:

- The Hanover Stock Exchange of Lower Saxony (Niedersächsische Börse zu Hannover), Germany

Dietmar Müller

Positions held within the Group:
None

External positions:

Deputy member of the General Assembly of:

- Gesellschaft für Gemeindeentwicklung und Wirtschaftsförderung Gleichen mbH (company for community and business development), Germany

Ilke Hildegard Panzer

None

Frank Riemensperger

Positions held within the Group:
None

External positions:

On the Supervisory Board of:

- DRM Datenraum Mobilität GmbH, Germany
- Drägerwerk Verwaltungs AG, Germany (since May 5, 2023)
- Dräger Safety Verwaltungs AG, Germany (since May 5, 2023)

Hermann Jens Ritzau

None

Prof. Dr. Klaus Rüdiger Trützscher

Positions held within the Group:
None

External positions:

On the Supervisory Board of:

- Zwiesel Kristallglas AG, Germany, Chairman (until December 31, 2023)

On the Beirat (Advisory Board) of:

- Odenwald Faserplatten GmbH, Germany (until June 20, 2023)

Sabrina Wirth

Positions held within the Group:

None

External positions:

On the Beirat (Advisory Board) of:

- Investitions- und Förderbank Niedersachsen (NBank), Germany (since April 1, 2023)

About This Publication

Published by

Sartorius AG
Corporate Communications
37070 Göttingen, Germany

Editorial Deadline

February 15, 2024

Published on

February 16, 2024

This English translation is also available in German as the original language of this publication.

Sartorius AG

Otto-Brenner-Straße 20
37079 Göttingen

Telefon: +49.551.308.0
Fax: +49.551.308.3289

info@sartorius.com
www.sartorius.com